CN1291722C - Use of oligoxylose in preparing medicine for treating diabetes - Google Patents
Use of oligoxylose in preparing medicine for treating diabetes Download PDFInfo
- Publication number
- CN1291722C CN1291722C CN 200410008797 CN200410008797A CN1291722C CN 1291722 C CN1291722 C CN 1291722C CN 200410008797 CN200410008797 CN 200410008797 CN 200410008797 A CN200410008797 A CN 200410008797A CN 1291722 C CN1291722 C CN 1291722C
- Authority
- CN
- China
- Prior art keywords
- parts
- xylo
- oligosaccharide
- medicines
- oligomeric xylose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides the application of xylo-oligosaccharide to preparing medicines for treating diabetes, which relates to the application of the xylo-oligosaccharide in the technical field of pharmacy. The xylo-oligosaccharide can be used independently or used by matching with other medicines in a conventional preparation technology to prepare medicines of various kinds of preparation for clinical application, such as medicinal powder, pills, capsules, tablets, microcapsules, soft capsules, granules, etc. According to the test results, the xylo-oligosaccharide can improve the absorption of Chinese traditional medicines by the intestinal tract, and can obtain affirmative effects on diabetes treatment and blood glucose stabilization treatment when matched with Chinese traditional medicines. The xylo-oligosaccharide has the advantages of good stability and low intake, and is an uncommon and good auxiliary medicine for reducing blood glucose.
Description
Technical field
The present invention relates to the application of oligomeric xylose in pharmaceutical field.
Background technology
Along with the aging of world population, diabetes have become a kind of commonly encountered diseases, frequently-occurring disease, and its sickness rate is in rising trend in industrially developed country.The whole world has 1.2 hundred million diabeticss approximately, and 80% is non-insulin-dependent diabetes mellitus (2 type), and wherein China has 2,000 ten thousand, and the U.S. has 1,300 ten thousand, and Japan has 5,000,000.Because the death toll that diabetic complication causes has been to be listed as the 3rd after cardiovascular and cerebrovascular disease, cancer in developed country, has caused the great attention of countries in the world, numerous and confused pathogenesis to diabetes, medical treatment etc. are studied.Because its pathogenesis is still not fully aware of, mainly be to utilize the rising of medicine blood sugar control and prevent and treat complication at present.
The present invention relates to oligomeric xylose (xylooligosaccharide), it claims xylooligosaccharide again, is with β (1 by 2-7 xylose molecule, 4) functional oligose of glycosidic bond be combined into, wherein based on disaccharide and trisaccharide, its sugariness is 50% of a sucrose, pure taste, similar sucrose.The oligomeric xylose that relates in the present patent application is an example with the xylo-oligosaccharide powder of 95% purity all, and other oligomeric xylose can be converted according to the difference of content.
Summary of the invention
A kind of new purposes that the purpose of this invention is to provide oligomeric xylose, the especially application in the medicine of the effective treatment of preparation diabetes.
The invention discloses the application of a kind of oligomeric xylose in the medicine of preparation treatment diabetes.
The raw material of preparation treatment diabetes medicament comprises: 1～2 part of oligomeric xylose, and 20～60 parts of the Radixs Astragali, 10～30 parts in the Radix Rehmanniae, 10～30 parts of Fructus Lyciis, described umber is weight portion.Also can comprise Radix Ginseng and other adjuvant in the described pharmaceutical raw material.
The pharmacology of each raw material is as follows:
Oligomeric xylose is with β (1 by 2-7 xylose molecule, 4) functional oligose of glycosidic bond be combined into, wherein the content of disaccharide and trisaccharide is more than 50%, can regulate intestinal microbial population strongly, improve the absorbing environmental of medicine, strengthen the assimilation effect of medicine,, the effect of obvious enhancing drug effect is arranged especially to the absorption of Chinese medicine.
The Radix Astragali, the name Radix Astragali originates in China Shanxi Province, is a kind of famous and precious Chinese herbal medicine, has hidroschesis, diuresis, invigorating QI to consolidate the body surface resistance, toxin expelling row is dense, functions such as life, blood pressure lowering, antiabortive and the liver protecting.Modern medicine studies show that the Radix Astragali also has the human body of adjusting immune effect, and biological function is had significant strong effect.
The Radix Rehmanniae is a kind of Chinese herbal medicine that protects cloudy heat clearing away effect that has.
Fructus Lycii: sweet in the mouth, property is flat.Return liver, kidney channel.Kidney nourishing and replenishing vital essence is arranged, the effect of nourishing the liver to improve visual acuity.Pharmacology: the promotion immunization is arranged, reduce serum cholesterol, hepatic injury is had protective effect, significantly lasting hypoglycemic activity is arranged.
Radix Ginseng: sweet in the mouth, little hardship, slightly warm in nature.Return lung, spleen channel.The effect that strongly invigorating primordial QI, tonifying the lung spleen invigorating, promoting the production of body fluid to quench thirst, the Fructus Alpiniae Oxyphyllae of calming the nerves are arranged.Clinically be used for the treatment of the vigour sudden collapse, yang-energy is died cruelly; The deficiency of the lung breath with cough prolonged illness, voice low timid, hinder in calentura Tianjin, thirsty lip is dry; Useful in addition air mass dashes, and nourishing blood and preventing abortion, the strong effect of tonification can be in order to allaying tiredness, strengthen the resistivity of human body to harmful factor, improves cold high pressure or low pressure, anoxia, anxiety, loses blood and the toleration of toxic poisoning.Pharmacology: Radix Ginseng can improve central nervous system's process of excitation, also can strengthen process of inhibition, and is relevant with the intelligence and the antifatigue effect that improve the people; Can be excited myocardium, improve the diseased heart function, alleviate experimental cardiac damage; Strengthen the resistivity of human body, the effect of the former state of adaptation is arranged harmful factor; Erythrocyte, hemoglobin cell are increased, alleviate the infringement of radiation hemopoietic system; Radix Ginseng has the human immunity of enhancing and antitumaous effect.
In the prior art, never there is the simple combination of human three flavor Chinese medicines to treat diabetes, and in the present invention, the adding of oligomeric xylose can promote the absorption of Chinese medicine effectively, improves the drug effect of Chinese medicine, play several flavor Chinese medicines the effect that can not play, evidence, after adding oligomeric xylose, the drug effect of described pharmaceutical composition obviously improves, and has played mutual synergism.
The specific embodiment
The oligomeric xylose that relates among the present invention can be bought from the market, as buying the oligomeric xylose that Beijing Ao Qi biotech firm produces.Other raw material of Chinese medicine that relate among the present invention can be purchased in each big pharmacy.
The basic production technological process of oligomeric xylose is roughly as follows: with the corn cob remove impurity, pulverizing the back handles and washes with saturated high-temperature water vapor, then the Semen Maydis powder after sizing mixing is carried out highly compressed steaming and decocting, mixture after the steaming and decocting is through after the vapor-liquid separation, in liquid, add purified hydrolytic enzyme liquid, under the effect of steam, carry out enzymolysis, through behind 4-8 hour the enzymolysis mother solution is carried out sterilization treatment, add water then and remove bits, then to the processing of decolouring of the mother solution of xylose, secondary filter, ion exchange, vacuum concentration has just obtained 70% oligomeric xylose slurry, reconcentration just can obtain 95% oligomeric xylose slurry, just can obtain the xylo-oligosaccharide powder of 70% purity and 95% purity respectively through dusting, carry out metering packing and warehouse-in at last.
When using oligomeric xylose,, oligomeric xylose and other Chinese medicines are mixed with the medicine of operable various different dosage forms clinically, as powder, pill, capsule, tablet, microcapsule, soft capsule, electuary etc. with the preparation process of routine.
The weight proportion of each raw material can be:
2 parts of oligomeric xyloses, 20 parts of the Radixs Astragali, 10 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis;
2 parts of oligomeric xyloses, 60 parts of the Radixs Astragali, 30 parts in the Radix Rehmanniae, 30 parts of Fructus Lyciis;
1 part of oligomeric xylose, 20 parts of the Radixs Astragali, 10 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis;
1 part of oligomeric xylose, 20 parts of the Radixs Astragali, 20 parts in the Radix Rehmanniae, 20 parts of Fructus Lyciis;
1 part of oligomeric xylose, 20 parts of the Radixs Astragali, 25 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis;
1 part of oligomeric xylose, 20 parts of the Radixs Astragali, 25 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis, 10 parts of Radix Ginsengs;
1 part of oligomeric xylose, 20 parts of the Radixs Astragali, 25 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis, 20 parts of Radix Ginsengs;
2 parts of oligomeric xyloses, 20 parts of the Radixs Astragali, 25 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis, 10 parts of Radix Ginsengs;
2 parts of oligomeric xyloses, 20 parts of the Radixs Astragali, 25 parts in the Radix Rehmanniae, 10 parts of Fructus Lyciis, 30 parts of Radix Ginsengs.
Verify that below by concrete test oligomeric xylose controls effect in the medicine of diabetes in preparation.
Between in August, 2003 to 2003 year December, select 2 tame hospital outpatient and inpatients, age 30-50 year, qualified case 60 examples.60 routine case diabeticss by oral acarbose blood sugar lowering and stable blood glucose, are withdrawn the flat blood sugar increasing of blood sugar lowering on ordinary days.
60 routine patients are divided into 4 groups at random, every group 15 routine patient:
First group of patient: change the clothes Radix Astragali 20g every day, the electuary that Radix Rehmanniae 10g and Fructus Lycii 10g make substitutes the acarbose blood sugar lowering fully, and 15 routine patient's blood glucose can not be controlled fully, and 11 routine patient's blood glucose surpass 160mg/ml after the meal; 4 routine patient's blood glucose surpass 140mg/ml.(contrast groups)
Second group of patient: change the clothes Radix Astragali 20g every day, Radix Rehmanniae 10g, the electuary that Fructus Lycii 10g and Radix Ginseng 10g make substitutes the acarbose blood sugar lowering fully, and 15 routine patient's blood glucose can not be controlled fully, and 9 routine patient's blood glucose surpass 150mg/ml after the meal; 6 routine patient's blood glucose surpass 160mg/ml.(contrast groups)
The 3rd group of patient: change clothes oligomeric xylose 2g every day, Radix Astragali 20g, the electuary that Radix Rehmanniae 10g and Fructus Lycii 10g make substitutes the acarbose blood sugar lowering fully, and 15 routine patient's blood glucose are controlled fully, and post-prandial glycemia is all below 150mg/ml.
The 4th group of patient: change clothes oligomeric xylose 2g every day, Radix Astragali 20g, Radix Rehmanniae 10g, the electuary that Fructus Lycii 10g and Radix Ginseng 10g make substitutes the acarbose blood sugar lowering fully, and 15 routine patient's blood glucose are controlled fully, and post-prandial glycemia is all below 150mg/ml.
Test of the present invention has convincingly demonstrated oligomeric xylose and has controlled the outstanding role of bringing into play in the medicine of diabetes in preparation, and assimilation effect and traditional blood-sugar lowering tcm drug that it has strengthened Chinese medicine bring out the best in each other.
Claims (2)
1. the application of oligomeric xylose in the medicine of preparation treatment diabetes, it is as follows to it is characterized in that preparing the raw material basis for the treatment of diabetes medicament: 1～2 part of oligomeric xylose, 20～60 parts of the Radixs Astragali, 10～30 parts in the Radix Rehmanniae, 10～30 parts of Fructus Lyciis, described umber is weight portion.
2. the application of oligomeric xylose in the medicine of preparation treatment diabetes, it is as follows to it is characterized in that preparing the raw material basis for the treatment of diabetes medicament: 1～2 part of oligomeric xylose, 20～60 parts of the Radixs Astragali, 10～30 parts in the Radix Rehmanniae, 10～30 parts of Fructus Lyciis, 10～30 parts of Radix Ginsengs, described umber is weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410008797 CN1291722C (en) | 2004-03-19 | 2004-03-19 | Use of oligoxylose in preparing medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410008797 CN1291722C (en) | 2004-03-19 | 2004-03-19 | Use of oligoxylose in preparing medicine for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562048A CN1562048A (en) | 2005-01-12 |
| CN1291722C true CN1291722C (en) | 2006-12-27 |
Family
ID=34477731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410008797 Expired - Fee Related CN1291722C (en) | 2004-03-19 | 2004-03-19 | Use of oligoxylose in preparing medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291722C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313029C (en) * | 2005-04-05 | 2007-05-02 | 山东龙力生物科技有限公司 | Health products adapted for diabetic and production method thereof |
-
2004
- 2004-03-19 CN CN 200410008797 patent/CN1291722C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1562048A (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102271698B (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN104857436B (en) | Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN1291722C (en) | Use of oligoxylose in preparing medicine for treating diabetes | |
| CN102228620B (en) | Chinese medicinal compound preparation having the functions of supplementing iron and enriching the blood and preparation method thereof | |
| CN102370677A (en) | Three-flavor sandalwood preparation and preparation method thereof | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| KR100979882B1 (en) | Compositions for preventing and curing diabetes comprising extracts of Lonicera japonica and Panax ginseng C.A. Meyer | |
| CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN101062328A (en) | Chinese traditional combination having anti-alcohol function | |
| CN114259540B (en) | Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof | |
| CN1181876C (en) | Medicine for curing diabetes and its preparing method | |
| CN107281408A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN101745010B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN100502927C (en) | Medication of three gen-seng and astragalus root and its preparation method | |
| CN1363386A (en) | Composition Chinese-medicinal herb pieces and preparing process thereof | |
| CN1306830A (en) | Medicine for treating type II diabetes | |
| CN105796952A (en) | Gliquidone-containing medicine combination for treating diabetes and preparation method thereof | |
| CN1970034B (en) | Chinese medicine containing gadol and tuckahoe | |
| CN105250919B (en) | It is a kind of for preventing and/or the Chinese medicine composition for treating liver disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Pengsong Document name: Notification of registration procedures and notice of patent for invention Addressee: Ji Pengsong Document name: Notice of conformity |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Pengsong Document name: patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Pengsong Document name: patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Pengsong Document name: payment instructions |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Pengsong Document name: Notification of Termination of Patent Right |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Ji Pengsong Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |